Study: NCT03500133

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No radiotherapy if CR at the end of chemotherapy.
Description: Adapted chemotherapy without radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No radiotherapy if CR at the end of chemotherapy.
Description: Adapted chemotherapy without radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No radiotherapy if CR at the end of chemotherapy.
Description: Adapted chemotherapy without radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No radiotherapy if CR at the end of chemotherapy.
Description: Adapted chemotherapy without radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No radiotherapy if CR at the end of chemotherapy.
Description: Adapted chemotherapy without radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No radiotherapy if CR at the end of chemotherapy.
Description: Adapted chemotherapy without radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No radiotherapy if CR at the end of chemotherapy.
Description: Adapted chemotherapy without radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
Description: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
Description: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IN 30Gy RT in case of PR at the end of chemotherapy
Description: Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IN 30Gy RT in case of PR at the end of chemotherapy
Description: Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IN 30Gy RT in case of PR at the end of chemotherapy
Description: Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
Description: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Description: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Description: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
Description: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Description: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.